Please login to the form below

Not currently logged in
Email:
Password:

Amryt Pharma appoints new regulatory affairs head

Derval O’Carroll joins the rare disease-focused biopharma from Retrophin

Rare and orphan disease-focused biopharmaceutical group Amryt Pharma has appointed a new head of regulatory affairs in the form of Derval O’Carroll.

O’Carroll has over 25 years’ experience in the pharmaceutical industry and regulatory affairs business. Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin.

Her previous roles have seen her provide regulatory, strategic and operational input to product teams and managing development-stage and commercial products.

Prior to her time at Retrophin, O’Carroll spent eleven years as a managing consultant at Real Regulatory, a consultancy specialising in European regulatory affairs, quality management systems and supply chain operations compliance.

Her new role will see her take responsibility for engagement with regulatory agencies and she will examine opportunities to pursue new orphan indications for Amryt’s Epidermolysis bullosa candidate.

Dr Joe Wiley, chief executive officer or Amryt Pharma, said: “We are delighted to further strengthen our senior management team with the appointment of Derval as head of regulatory affairs.

“Her expertise will be particularly valuable as we plan for completion of our ongoing AP101 phase III trial in EB.”

1st February 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics